Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles (Q34772727)

4 August 2017

title

Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles (English)

1 reference

4 August 2017

0 references

11

David C Montefiori

1 reference

4 August 2017

19

Bernard Moss

1 reference

4 August 2017

15

Lindsey R Baden

1 reference

4 August 2017

18

Linda S Wyatt

1 reference

4 August 2017

10

Georgia D Tomaras

1 reference

4 August 2017

Harriet L Robinson

20

0 references

Lilin Lai

object named as

Lilin Lai

13

0 references

Sharon E Frey

16

object named as

Sharon E Frey

1 reference

4 August 2017

14

Spyros A Kalams

1 reference

4 August 2017

Paul A Goepfert

1

1 reference

4 August 2017

Marnie L Elizaga

2

1 reference

4 August 2017

Alicia Sato

3

1 reference

4 August 2017

Li Qin

4

1 reference

4 August 2017

Massimo Cardinali

5

1 reference

4 August 2017

Christine M Hay

6

1 reference

4 August 2017

John Hural

7

1 reference

4 August 2017

Stephen C DeRosa

8

1 reference

4 August 2017

Olivier D DeFawe

9

1 reference

4 August 2017

Yongxian Xu

12

1 reference

4 August 2017

William A Blattner

17

1 reference

4 August 2017

National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network

21

1 reference

4 August 2017

language of work or name

English

0 references

publication date

31 January 2011

1 reference

4 August 2017

number of pages

10

1 reference

Journal of Infectious Diseases

inferred from page(s)

published in

1 reference

4 August 2017

volume

203

1 reference

4 August 2017

issue

5

1 reference

4 August 2017

page(s)

610-619

1 reference

Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys

4 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072720

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072720

Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072720

Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072720

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072720

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072720

Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072720

Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072720

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072720

Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072720

Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072720

GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072720

Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072720

Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072720

Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072720

Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072720

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072720

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072720

ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072720

Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072720

Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3072720

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

7 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ105

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ105

DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ105

Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ105

Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ105

Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ105

Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ105

Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ105

Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ105

EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ105

Equivalent Immunogenicity of the Highly Attenuated Poxvirus-Based ALVAC-SIV and NYVAC-SIV Vaccine Candidates in SIVmac251-Infected Macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ105

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FINFDIS%2FJIQ105

High‐Dose Recombinant Canarypox Vaccine Expressing HIV‐1 Protein, in Seronegative Human Subjects

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21282192

12 December 2020

inferred from PubMed ID database lookup

HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21282192

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1093/INFDIS/JIQ105

1 reference

release_xq7yeksmfzdilgdwqut43evuwi

4 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xq7yeksmfzdilgdwqut43evuwi

24 November 2022

mapped directly with Wikidata item

PMC publication ID

3072720

1 reference

4 August 2017

1 reference